Chemotherapy of metastatic testicular cancer

Current status and future prospects

Thomas S. Stanton, Edith A. Perez, David R Gandara

Research output: Contribution to journalArticle

3 Citations (Scopus)

Abstract

Introduction of the chemotherapeutic agent cisplatin in 1974 initiated 15 years of progress in the management of metastatic testicular cancer at a pace virtually unprecedented in the history of medical oncology. With current cisplatin- and etoposide-based regimens, longterm survival of 80% is consistently achieved. Recently completed clinical trials have defined several prognostic variables that disthinguish good- and poor-prognosis subsets of patients. Since the great majority of patients with good-prognosis disease achieve complete remission and long-term survival, the current focus of research in this patient population has shifted to means of reducing treatment-related toxicity. By comparison, in poor-prognosis patients the cure rate remains an unacceptable 40%-50%. Clinical research in this population has focused primarily on methods of intensifying treatment, such as alternating non-cross-resistant drug combinations, increasing the dose intensity of cisplatin, and investigating new active agents such as ifosfamide. Even in the setting of relapsed or resistant disease, high-dose chemotherapy with or without autologous bone marrow transplant offers the potential for long-term remission in some patients. Future prospects for improving the therapeutic index may include colony-stimulating-factor support to circumvent chemotherapy-related myelosuppression, the use of chemosensitizers to reverse drug resistance, or the introduction of biologic response modifiers into the therapeutic armamentarium.

Original languageEnglish (US)
Pages (from-to)20-26
Number of pages7
JournalWorld Journal of Urology
Volume8
Issue number1
DOIs
StatePublished - Mar 1990

Fingerprint

Testicular Neoplasms
Drug Therapy
Cisplatin
Colony-Stimulating Factors
Ifosfamide
Survival
Medical Oncology
Etoposide
Drug Combinations
Therapeutics
Research
Drug Resistance
Population
Bone Marrow
History
Clinical Trials
Transplants

ASJC Scopus subject areas

  • Urology

Cite this

Chemotherapy of metastatic testicular cancer : Current status and future prospects. / Stanton, Thomas S.; Perez, Edith A.; Gandara, David R.

In: World Journal of Urology, Vol. 8, No. 1, 03.1990, p. 20-26.

Research output: Contribution to journalArticle

@article{97b6ade21318484998e8e955a194a9e4,
title = "Chemotherapy of metastatic testicular cancer: Current status and future prospects",
abstract = "Introduction of the chemotherapeutic agent cisplatin in 1974 initiated 15 years of progress in the management of metastatic testicular cancer at a pace virtually unprecedented in the history of medical oncology. With current cisplatin- and etoposide-based regimens, longterm survival of 80{\%} is consistently achieved. Recently completed clinical trials have defined several prognostic variables that disthinguish good- and poor-prognosis subsets of patients. Since the great majority of patients with good-prognosis disease achieve complete remission and long-term survival, the current focus of research in this patient population has shifted to means of reducing treatment-related toxicity. By comparison, in poor-prognosis patients the cure rate remains an unacceptable 40{\%}-50{\%}. Clinical research in this population has focused primarily on methods of intensifying treatment, such as alternating non-cross-resistant drug combinations, increasing the dose intensity of cisplatin, and investigating new active agents such as ifosfamide. Even in the setting of relapsed or resistant disease, high-dose chemotherapy with or without autologous bone marrow transplant offers the potential for long-term remission in some patients. Future prospects for improving the therapeutic index may include colony-stimulating-factor support to circumvent chemotherapy-related myelosuppression, the use of chemosensitizers to reverse drug resistance, or the introduction of biologic response modifiers into the therapeutic armamentarium.",
author = "Stanton, {Thomas S.} and Perez, {Edith A.} and Gandara, {David R}",
year = "1990",
month = "3",
doi = "10.1007/BF01576273",
language = "English (US)",
volume = "8",
pages = "20--26",
journal = "World Journal of Urology",
issn = "0724-4983",
publisher = "Springer Verlag",
number = "1",

}

TY - JOUR

T1 - Chemotherapy of metastatic testicular cancer

T2 - Current status and future prospects

AU - Stanton, Thomas S.

AU - Perez, Edith A.

AU - Gandara, David R

PY - 1990/3

Y1 - 1990/3

N2 - Introduction of the chemotherapeutic agent cisplatin in 1974 initiated 15 years of progress in the management of metastatic testicular cancer at a pace virtually unprecedented in the history of medical oncology. With current cisplatin- and etoposide-based regimens, longterm survival of 80% is consistently achieved. Recently completed clinical trials have defined several prognostic variables that disthinguish good- and poor-prognosis subsets of patients. Since the great majority of patients with good-prognosis disease achieve complete remission and long-term survival, the current focus of research in this patient population has shifted to means of reducing treatment-related toxicity. By comparison, in poor-prognosis patients the cure rate remains an unacceptable 40%-50%. Clinical research in this population has focused primarily on methods of intensifying treatment, such as alternating non-cross-resistant drug combinations, increasing the dose intensity of cisplatin, and investigating new active agents such as ifosfamide. Even in the setting of relapsed or resistant disease, high-dose chemotherapy with or without autologous bone marrow transplant offers the potential for long-term remission in some patients. Future prospects for improving the therapeutic index may include colony-stimulating-factor support to circumvent chemotherapy-related myelosuppression, the use of chemosensitizers to reverse drug resistance, or the introduction of biologic response modifiers into the therapeutic armamentarium.

AB - Introduction of the chemotherapeutic agent cisplatin in 1974 initiated 15 years of progress in the management of metastatic testicular cancer at a pace virtually unprecedented in the history of medical oncology. With current cisplatin- and etoposide-based regimens, longterm survival of 80% is consistently achieved. Recently completed clinical trials have defined several prognostic variables that disthinguish good- and poor-prognosis subsets of patients. Since the great majority of patients with good-prognosis disease achieve complete remission and long-term survival, the current focus of research in this patient population has shifted to means of reducing treatment-related toxicity. By comparison, in poor-prognosis patients the cure rate remains an unacceptable 40%-50%. Clinical research in this population has focused primarily on methods of intensifying treatment, such as alternating non-cross-resistant drug combinations, increasing the dose intensity of cisplatin, and investigating new active agents such as ifosfamide. Even in the setting of relapsed or resistant disease, high-dose chemotherapy with or without autologous bone marrow transplant offers the potential for long-term remission in some patients. Future prospects for improving the therapeutic index may include colony-stimulating-factor support to circumvent chemotherapy-related myelosuppression, the use of chemosensitizers to reverse drug resistance, or the introduction of biologic response modifiers into the therapeutic armamentarium.

UR - http://www.scopus.com/inward/record.url?scp=0025280152&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0025280152&partnerID=8YFLogxK

U2 - 10.1007/BF01576273

DO - 10.1007/BF01576273

M3 - Article

VL - 8

SP - 20

EP - 26

JO - World Journal of Urology

JF - World Journal of Urology

SN - 0724-4983

IS - 1

ER -